)
Visual21 Nov 2025
Data center suppliers
Spero Therapeutics (SPRO) investor relations material
Spero Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary13 Nov, 2025
Executive summary
Focus shifted to tebipenem HBr after ceasing development of SPR720 and SPR206; business now highly dependent on tebipenem HBr and collaboration with GSK.
Pivotal Phase 3 PIVOT-PO trial for tebipenem HBr met its primary endpoint, showing non-inferiority to IV imipenem-cilastatin, and was stopped early for efficacy; results presented at IDWeek 2025.
GSK, the development partner, plans to submit an FDA filing for tebipenem HBr in Q4 2025, with a regulatory decision expected in 2H 2026.
Accumulated deficit reached $482.6 million as of September 30, 2025; cash and cash equivalents were $48.6 million.
Restructuring in late 2024 reduced workforce and costs, with $1.1 million in related expenses recognized by Q3 2025.
Financial highlights
Total revenue for Q3 2025 was $5.4 million, down from $13.5 million in Q3 2024, mainly due to lower collaboration and grant revenue.
Net loss for Q3 2025 was $7.4 million, improved from $17.1 million in Q3 2024; net loss for the nine months was $22.9 million, improved from $47.7 million in the prior year.
Research and development expenses for the nine months ended September 30, 2025, were $32.9 million, down from $67.9 million in 2024, reflecting reduced clinical activity and SPR720 program costs.
General and administrative expenses for the nine months were $16.9 million, flat year-over-year; Q3 2025 expenses decreased to $4.2 million from $5.2 million year-over-year.
Cash and cash equivalents at September 30, 2025: $48.6 million.
Outlook and guidance
Cash runway expected to fund operations and capital expenditures into 2028, assuming current plans and no major changes.
Additional funding will be required beyond this period or if operating plans change; options include equity, debt, collaborations, or further cost reductions.
Focus remains on completing obligations under the GSK License Agreement and supporting FDA submission for tebipenem HBr.
Anticipates FDA submission for tebipenem HBr in Q4 2025 and regulatory decision in 2H 2026.
Tebipenem HBr value proposition
Impact of SPR720 program discontinuation
Factors extending cash runway into 2028?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Spero Therapeutics earnings date
Q4 202513 Mar, 2026
Next Spero Therapeutics earnings date
Q4 202513 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Spero Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for bacterial infections, including multi-drug-resistant bacterial infections. The company's pipeline includes both oral and intravenous antibiotic candidates designed to address serious and difficult-to-treat infections. Spero's lead programs target conditions such as urinary tract infections and hospital-acquired bacterial infections, with an emphasis on addressing the growing challenge of antibiotic resistance. The company’s research and development efforts aim to provide new therapeutic options in areas with high unmet medical needs. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage